Molina won’t rule out return to certain ACA markets

Managed care and Affordable Care Act (ACA) exchange insurer Molina Healthcare said its first quarter profits “exceed expectations” after raising premiums for its marketplace plans by about 60 percent and isn’t ruling out returning to markets in Utah and Wisconsin, where it previously offered coverage. 

Forbes reports Molina is “taking a cautious view” towards its ACA business for the rest of the year, but acknowledged its enrollment beat projections by 50,000 customers. The insurer had been profitable on the exchanges in their early years on slim margins of 1.5 to 2 percent, but a reversal in fortunes led to the company forcing out CEO J. Mario Molina, MD and CFO John Molina, sons of founder C. David Molina, MD. The insurer then cut 1,400 employees—10 percent of its workforce in the corporate and health plan division—while the ousted CEO claimed the company may be sold and his outspoken support of the ACA may have led to his departure.

For 2018, Molina has about 450,000 ACA enrollees, less than half of its membership in 2017. Premium revenue was down 7 percent in the first quarter, but net income rose to $107 million.

While small insurers like Molina and Centene have found a winning strategy on the ACA markets—particularly when they’re the only insurer offering plans in an area—larger insurers have also benefitted from rushing to leave the exchanges. Anthem, for example, reported a 30 percent increase in first quarter profits despite its enrollment decreasing by one million after significantly reducing its ACA presence.

Read more at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.